New research shows combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to offer additional protection against heart and kidney disease in patients with diabetes.1 Findings were published today in The Lancet Diabetes & Endocrinology and presented in May at the 61st European Renal Association Congress in Stockholm, Sweden.
New research shows combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to offer additional protection against heart and kidney disease in patients with diabetes.1 Findings were published today in The Lancet Diabetes & Endocrinology and presented in May at the 61st European Renal Association Congress in Stockholm, Sweden.
SGLT2is, also called gliflozins, are a class of drug that lower blood glucose by increasing its excretion in the urine, while GLP-1RAs, such as Ozempic, work by enhancing insulin release and sensitivity. Both classes of medicine have each been shown to improve cardiovascular outcomes. Although small, relatively short-term trials have suggested that using these medicines together improves blood glucose control, their combined effects on heart disease and kidney failure are less clear.
Researchers involved in the SGLT2 Inhibitor Meta-analysis Cardio-Renal Trialists’ Consortium (SMART-C) pooled data across 12 large-scale, placebo-controlled trials of SGLT2is involving 73,238 patients with diabetes, 3,065 of whom were already receiving GLP1-RAs. The meta-analysis showed that the benefits of SGLT2is were observed independent of GLP1-RA use.
SGLT2is reduced the risk of major adverse cardiovascular events (myocardial infarction, stroke, or cardiovascular death) by 11% and hospitalisation for heart failure or cardiovascular death by 23% versus placebo, even when added to GLP1-RAs. SGLT2is also reduced the risk of chronic kidney disease progression by 33% when added to GLP1-RAs and slowed the annual loss of kidney function by almost 60% when added to GLP-1RAs. No new safety concerns were identified when SGLT2is and GLP-1RAs were used in combination.
Clinical Associate Professor Brendon Neuen, Senior Research Fellow at The George Institute for Global Health, Director of Kidney Trials at Sydney’s Royal North Shore Hospital, and lead author on the paper said, “Given the rapidly expanding indications for the use of GLP-1 receptor agonists, it was important to look at their effects with SGLT2 inhibitors. This study represents the largest and most comprehensive assessment of clinical outcomes for this combination of medicines.”
A/Prof Neuen added that both classes of medicines work independently of each other: “SGLT2 inhibitors have clear protective effects against heart failure and chronic kidney disease, while GLP-1 receptor agonists can reduce the risk of heart attack, stroke, and also kidney disease – as recently demonstrated in the landmark FLOW trial.2 Our findings support using this combination to further improve outcomes in patients with type 2 diabetes who meet guideline recommendations for both therapies.”
Diabetes is a known risk factor for cardiovascular and kidney disease, with impaired glucose control causing damage to blood vessels in the heart and kidneys. Many patients with diabetes live with cardiovascular disease or chronic kidney disease, with prevalence increasing in the years following a diabetes diagnosis.3
SMART-C is co-chaired by A/Prof Brendon Neuen and Prof Hiddo Heerspink of The George Institute for Global Health.
-ends-
References
- Apperloo E, Neuen BL et al. Efficacy and safety of sodium glucose co-transporter 2 inhibitors with and without glucagon-like peptide-1 receptor agonists: A SMART-C collaborative meta-analysis of randomised controlled trials. The Lancet. 2024.
- Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. NEJM. 2024.
- Pearson-Stuttard J, et al. Variations in comorbidity burden in people with type 2 diabetes over disease duration: A population-based analysis of real world evidence. EClinicalMedicine. 2022.
Journal
The Lancet Diabetes & Endocrinology
Method of Research
Meta-analysis
Subject of Research
Animals
Article Title
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
Article Publication Date
8-Jul-2024
COI Statement
BLN reports fees for travel support, advisory boards, scientific presentations, and steering committee roles from AstraZeneca, Alexion, Bayer, Boehringer and Ingelheim, Cambridge Healthcare Research, Cornerstone Medical Education, Janssen, the limbic, Medscape, Novo Nordisk, and Travere Therapeutics with all honoraria paid to The George Institute for Global Health. RAF has received studentship awards from the HDR-UK-Turing Wellcome Programme
in Health Data Science. SDA reports grants and personal fees from Vifor and Abbott Vascular; and personal fees for consultancies, trial committee work or lectures, or a combination, from Actimed, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Brahms, Cardiac Dimensions, Cardior, Cordio, CVRx, Cytokinetics, Edwards, Farraday
Pharmaceuticals, GSK, HeartKinetics, Impulse Dynamics, Occlutech, Pfizer, Regeneron, Repairon, Scirent, Sensible Medical, Servier, Vectorious, and V-Wave; and is the named co-inventor of two patent applications regarding MR-proANP (patent numbers DE 102007010834 and DE 102007022367), but he does not benefit personally from the related issued patents. DLB is on an advisory board for Angiowave, Bayer, Boehringer Ingelheim, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Stasys; is on the board of directors for American Heart Association New York City, Angiowave (stock options), Bristol Myers Squibb (stock), DRS. LINQ (stock options), High Enroll (stock); is a consultant for Broadview Ventures, GlaxoSmithKline, Hims, SFJ, Youngene; is on a data monitoring committee for Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical
Research Institute, for the PORTICO trial, funded by St Jude Medical, now Abbott), Boston Scientific (chair for the PEITHO trial), Cleveland Clinic, Contego Medical (chair for the PERFORMANCE 2 trial), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical; and for ALLAY-HF, funded by Alleviant Medical), Novartis, Population Health Research
Institute, Rutgers University (for the National Institutes for Healthfunded MINT trial); receives honoraria from the American College of Cardiology (senior associate editor for Clinical Trials and News for ACC.org; chair for the American College of Cardiology Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi and Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; for
the RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; and the AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor in chief for Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (American Heart Association lecture), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor in chief for the Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor and associate editor), K2P (co-chair for interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (Continuing Medical Education steering committees), MJH Life Sciences, Oakstone CME (course director for Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee,
steering committee, and USA national co-leader, funded by Bayer), WebMD (Continuing Medical Education steering committees), Wiley (steering committee), and Clinical Cardiology (deputy editor); is named on a patent for sotagliflozin assigned to Brigham and Women’s Hospital who assigned to Lexicon (neither DLB nor Brigham and Women’s Hospital receive any income from this patent); receives research funding from Abbott, Acesion Pharma, Afimmune, Aker
Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi,
Stasys, Synaptic, The Medicines Company, Youngene, 89Bio; receives royalties from Elsevier (editor for Braunwald’s Heart Disease); is a site co-investigator for Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions; is a trustee for the American College of Cardiology; and has conducted unfunded research with FlowCo. JB reports consulting fees from Abbott, American Regent, Amgen,
Applied Therapeutic, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardiocell, Cardior, CSL Bearing, CVRx, Cytokinetics, Daxor, Edwards, Element Science, Faraday, Foundry, G3P, Innolife, Impulse Dynamics, Imbria, Inventiva, Ionis, Lexicon, Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pharmacosmos, Pharmain, Pfizer, Prolaio, Regeneron, Renibus, Roche, Salamandra, Sanofi, SC Pharma, Secretome, Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vifor, and Zoll. DZIC has
received honoraria from Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, Abbvie, Janssen, Bayer, Prometic, BMS, Maze, Gilead, CSL-Behring, Otsuka, Novartis, Youngene, Lexicon, and Novo-Nordisk; and received operational funding for clinical trials from Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL-Behring, and Novo-Nordisk. WGH reports funding from the UK Medical Research Council, Kidney Research UK, and Health Data Research UK; and grants to the University of Oxford from Boehringer Ingelheim and Eli Lilly for the EMPA-KIDNEY trial. SEI reports serving as an advisor or consultant to Boehringer Ingelheim, AstraZeneca, Novo Nordisk, Merck, Pfizer, and
Bayer; and delivering lectures sponsored by Boehringer Ingelheim and AstraZeneca. MJJ is supported by an National Health and Medical Research Council investigator grant; is responsible for research projects that have received funding from Amgen, Baxter, CSL, Dimerix, Eli Lilly, Gambro, and MSD; and has received fees for advisory, steering committee, or scientific presentations, or a combination, from Akebia, Amgen, Astra Zeneca, Baxter, Bayer, Boehringer Ingelheim, Cesas Linx, Chinook, CSL, Janssen, Medscape, MSD, Occuryx, Roche, and Vifor, with any consultancy, honoraria, or
travel support paid to her institution. C-CL is an employee of Merck Sharp & Dohme, a subsidiary of Merck & Co. KWM has received research support from Afferent, Amgen, Apple, AstraZeneca, Cardiva Medical, Daiichi, Ferring, Google (Verily), Johnson & Johnson, Luitpold, Medtronic, Merck, National Institutes of Health, Novartis, Sanofi, St Jude, and Tenax; and has served as a consultant (speaker fees for continuing medical education events only) for Abbott, Ablynx,
AstraZeneca, Baim Institute, Boehringer Ingelheim, Bristol-Myers Squibb, Elsevier, GlaxoSmithKline, Johnson & Johnson, MedErgy, Medscape, Mitsubishi Tanabe, Myokardia, the National institutes for Health, Novartis, Novo Nordisk, Portola, Radiometer, Regeneron, Springer Publishing, and the University of California, San Francisco. DKM has received honoraria for trial leadership from Boehringer Ingelheim, Pfizer, AstraZeneca, Novo Nordisk, Esperion, Lilly USA,
CSL Behring, Eidos, and NewAmsterdam; and honoraria for consultancy from Lilly USA, Boehringer Ingelheim, Merck & Co, Novo Nordisk, Applied Therapeutics, CSL Behring, Bayer, Altimmune, Intercept, Alynlam, and Pfizer. JJVM has received payments through Glasgow University from work on clinical trials, consulting, and other activities from Amgen, AstraZeneca, Bayer, Cardurion, Cytokinetics, GSK, KBP Biosciences, and Novartis; has received personal consultancy fees from Alnylam Pharma, Bayer, BMS, George Clinical PTY, Ionis Pharma, Novartis, Regeneron Pharma, and River 2 Renal
Corporation; has received personal lecture fees from Abbott, Alkem Metabolics, AstraZeneca, Blue Ocean Scientific Solutions, Boehringer Ingelheim, Canadian Medical and Surgical Knowledge, Emcure Pharma, Eris Lifesciences, European Academy of Continuing Medical Education, Hikma Pharmaceuticals, Imagica health, Intas Pharma,
JB Chemicals & Pharma, Lupin Pharma, Medscape or Heart.Org, ProAdWise Communications, Radcliffe Cardiology, Sun Pharma, The Corpus, Translation Research Group, and Translational Medicine Academy; and is a director of Global Clinical Trial Partners. BN has received grants for CANVAS and CREDENCE; is on an advisory board and has received honoraria and travel reimbursement all from Janssen and all paid to his institution; has received research support from the Australian National Health and Medical Research Council Principal Research Fellowship and Janssen; and has served on advisory boards or has had involvement in continuing medical education programmes for Janssen, with any consultancy, honoraria, or travel support paid to his institution; and has institutional relationships with AbbVie,
Actelion, and Janssen. MP reports consulting to 89bio, AbbVie, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, AstraZeneca, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Imara, Lilly, Medtronic, MSD, Novartis, Reata, Relypsa, and Salamandra. VP serves as a board director for St Vincent’s Health Australia, Victor Chang Cardiac Research Institute, and Mindgardens; and has received honoraria for Steering Committee roles, scientific presentations, or advisory board attendance, or a combination, from Abbvie, Amgen, Astra Zeneca, Bayer, Baxter, Boehringer Ingelheim, Chinook, Durect, Eli Lilly, Gilead, GSK, Janssen, Merck, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Otsuka, Pharmalink, Pfizer, Reata, Travere, Relypsa, Roche, Sanofi, Servier, and Tricida. MSS reports research grant support through the Brigham and Women’s Hospital from Abbott, Amgen, Anthos Therapeutics, AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, Ionis, Merck, Novartis, Pfizer, Saghmos Therapeutics, and Verve Therapeutics; and
consulting for Amgen, Anthos Therapeutics, AstraZeneca, Beren Therapeutics, Boehringer Ingelheim, Dr Reddy’s Laboratories, Merck, Moderna, Novo Nordisk, Precision BioSciences, and Silence Therapeutics. SDS has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health and the
National Heart, Lung, and Blood Institute, Neurotronik, Novartis, Novo Nordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. NS reports institutional grant support from Boehringer Ingelheim, Lilly, and Novo Nordisk. MS serves as a consultant for, or has received research support from, or both, Lexicon, Esperion, Amarin, NewAmsterdam, Silence, Sanofi, Tourmaline, and Regeneron Pharmaceuticals. MV has received research grant support, served on advisory boards, or had speaker engagements with American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Chiesi, Cytokinetics,
Lexicon Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog
Health; and participates on clinical trial committees for studies sponsored by AstraZeneca, Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. CW reports personal fees from Boehringer Ingelheim, AstraZeneca, Eli Lilly and Company, MSD, and Bayer. DCW reports honoraria or consultancy fees, or both, from Amgen, AstraZeneca (ongoing), Astellas, Bayer, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Janssen, Mundipharma, MSD, Napp, Dohme, Takeda, Vifor Fresenius, and Zydus. SDW reports research grants from Amgen, AstraZeneca, Janssen, Merck, and Pfizer; and consulting fees or honoraria from Icon Clinical and Novo Nordisk, Varian, and Harvard Medical School. SDW’s spouse, Dr Caroline Fox is an employee of Vertex, and former employee of Flagship Pioneering and Merck. MSS and SDW are members of the TIMI Study Group, which has received institutional grant support through Brigham and Women’s Hospital from Abbott, Abiomed, Amgen, Anthos Therapeutics, ARCA Biopharma, AstraZeneca, Boehringer Ingelheim,
Daiichi-Sankyo, Ionis Pharmaceuticals, Janssen Research and Development, MedImmune, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, Saghmos Therapeutics, Softcell Medical, The Medicines Company, Verve Therapeutics, and Zora Biosciences. FZ reports personal fees from 89Bio, Abbott, Acceleron, Applied Therapeutics, Bayer, Betagenon, Boehringer, BMS, CVRx, Cambrian, Cardior, Cereno Pharmaceutical, Cellprothera, CEVA, Inventiva, KBP, Merck, NovoNordisk, Owkin, Otsuka, Roche Diagnostics, Northsea, and USa2; having stock options at G3Pharmaceutical; having equities at Cereno, Cardiorenal, and Eshmoun Clinical Research; and being the founder of Cardiovascular Clinical Trialists. HJLH has received grants or contracts from AstraZeneca, Boehringer Ingelheim, Janssen, and Novo Nordisk; consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, CSL Behring, Dimerix, Eli Lilly, Gilead, Janssen, Novo Nordisk, Novartis, and Travere Therapeutics; and payment or honoraria for speaking from AstraZeneca and Novo Nordisk. EMA and NJ declare no competing interests.
